Pharma Sales: Winter Withdrawal Brings March Pharma Sales Down | Delhi News

NEW DELHI: Poor sales of respiratory and anti-infectives due to waning winter pulled down domestic pharma retail market in March to a flat growth of 1.3% year-on-year. Typically, asthma and respiratory diseases abound during winter months, further complicated by the toxic air.
The poor showing comes on the back of the market posting a robust growth in the preceding months — 8% in Feb and nearly 20% in Jan, data culled from market research firm IQVIA said.Among top rankers, Foracort, used for asthma and respiratory issues, assumed the top slot in the market with a 10% growth year-on-year in March, netting Rs 73 crore sales. It was followed by popular antibiotic, Antibiotic and anti-diabetic Glycomet-GP, with sales of Rs 68 crore and Rs 66 crore, respectively during the month. Amont the top 10 brands, Udiliv — used for liver-related disorders — recorded highest growth of 23% during the month.
The market was impacted by a sharp decline of 8% and 7% in respiratory and anti-infective therapies. Cardiac, followed by dermatology, posted 8% and 6% growth and were among top-10 growing therapies in the Rs 17,500 crore market. Respiratory therapies, including anti-asthma drugs, had registered a 20% growth in Feb — ironically pointing to our struggle with the growing pollution levels during the winter months.
For five consecutive months, chronic therapy has outperformed acute therapy.

Leave a Comment

Your email address will not be published. Required fields are marked *